Get the Stockscreener App
1.10
7.84%
0.08
After Hours:
1.10
Oncolytics Biotech Inc stock is traded at $1.10, with a volume of 1.26M.
It is up +7.84% in the last 24 hours and up +11.79% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
1.26M
Relative Volume:
0.92
Market Cap:
$127.74M
Revenue:
-
Net Income/Loss:
$-21.32M
P/E Ratio:
-4.8998
EPS:
-0.2245
Net Cash Flow:
$-19.96M
1W Performance:
+21.43%
1M Performance:
+11.79%
6M Performance:
-9.09%
1Y Performance:
+92.11%
1-Day Range:
$1.01
$1.10
1-Week Range:
$0.90
$1.10
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Name
Oncolytics Biotech Inc
Sector
Industry
Phone
(403) 670-7377
Address
804, 322 - 11 AVENUE SW, CALGARY, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.10 | 118.45M | 0 | -21.32M | -19.96M | -0.2245 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst - MarketBeat
Published on: 2026-04-14 02:49:57 - baoquankhu1.vn
Equities Analysts Issue Forecasts for ONCY Q1 Earnings - MarketBeat
Growth Report: What is Oncolytics Biotech Incs market position2026 Top Gainers & Verified Short-Term Plans - baoquankhu1.vn
Aug Outlook: Is Oncolytics Biotech Inc forming a breakout patternDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Published on: 2026-04-11 14:11:15 - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $10 - Moomoo
ONCY Should I Buy - Intellectia AI
Oncolytic Virotherapy Market size to reach $111.76 Billion - openPR.com
Q1 Earnings Estimate for ONCY Issued By Zacks Research - MarketBeat
What is Zacks Research's Forecast for ONCY FY2026 Earnings? - MarketBeat
Lake Street Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Oncolytics Biotech Inc. Announces $75 Million Open Market Sale Agreement with Jefferies LLC - Minichart
Oncolytics Biotech Inc. (ONCY) latest stock news and headlines - Yahoo Finance Singapore
Oncolytics schedules FDA meeting on anal cancer drug pathway By Investing.com - Investing.com Canada
Oncolytics Biotech Establishes $75 Million ATM Offering - TipRanks
Oncolytics Biotech (NASDAQ: ONCY) sets up $75M ATM facility - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) launches $75M ATM with Jefferies - Stock Titan
ONCY Technical Analysis & Stock Price Forecast - Intellectia AI
Oncolytics (ONCY) Targets FDA Meeting for Pelareorep's Anal Canc - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart
Oncolytics (ONCY) Targets FDA Meeting for Pelareorep's Anal Cancer Pathway - GuruFocus
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Plans FDA Meeting for Pelareorep SCAC Study - tipranks.com
Oncolytics Biotech schedules Type C FDA meeting to discuss single-arm registrational study for pelareorep in anal cancer - TradingView — Track All Markets
Oncolytics Biotech (NASDAQ: ONCY) targets single-arm pivotal SCAC path - Stock Titan
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer - The Manila Times
Oncolytics Biotech Inc announces a meeting focused on its single-arm pivotal study of candidate drug Pelareorep in second-line and later metastatic colorectal adenocarcinoma (SCAC) patients - bitget.com
Oncolytics Biotech® Announces Type C FDA Meeting To Discuss Single-Arm Registrational Pathway For Pelareorep In Anal Cancer - TradingView — Track All Markets
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
[EFFECT] ONCOLYTICS BIOTECH INC SEC Filing - Stock Titan
Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer - Bitget
Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Oncolytics Biotech Inc. (ONCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oncolytics Biotech: Revenue and Earnings Analysts Forecasts Revisions | ONYN | US68237V1035 - marketscreener.com
Oncolytics Biotech Inc.: Performance & Quotes, ONCY Stock Price on Nasdaq Exchange - marketscreener.com
Oncolytics Biotech: Financial Data Forecasts Estimates and Expectations | ONYN | US68237V1035 - marketscreener.com
Oncolytics Biotech: Target Price Consensus and Analysts Recommendations | ONYN | US68237V1035 - marketscreener.com
Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate - Sahm
Oncolytics Biotech: Target Price Consensus and Analysts Recommendations | ONCY | US68237V1035 - marketscreener.com
Oncolytics Biotech Inc.: Financial Data Forecasts Estimates and Expectations | ONCY | US68237V1035 - marketscreener.com
Oncolytics Biotech: Revenue and Earnings Analysts Forecasts Revisions | ONCY | US68237V1035 - MarketScreener
Oncolytics Biotech Inc.: Fundamental Analysis and Financial Ratings | ONCY | US68237V1035 - marketscreener.com
ONCY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oncolytics Biotech Inc. (ONCY) stock price, news, quote and history - Yahoo Finance Singapore
Oncolytics Biotech Completes Domicile Change to the United States - marketscreener.com
Oncolytics Biotech® Completes Domicile Change to the United States - Sahm
Oncolytics completes reincorporation from Canada to Nevada By Investing.com - Investing.com South Africa
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):